(MedPage Today) — Adding the dual checkpoint inhibitor regimen of ipilimumab (Yervoy) and nivolumab (Opdivo) to percutaneous hepatic perfusion significantly reduced the risk of disease progression or death in metastatic uveal melanoma, a single…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
